# Talazoparib in advanced cancers with BRCA1/2, DNA repair and PTEN alterations

Source: https://onco.cc/key-papers/paper-piha-paul-talazoparib-ddr-npj-2024/  
OnCo record `paper-piha-paul-talazoparib-ddr-npj-2024` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Talazoparib helped some people with advanced cancers carrying tumour-only BRCA mutations. The study was small and included several cancer types.

## Summary

Phase 2 molecular basket, median four prior lines of therapy. Cohorts included somatic BRCA1/2, other homologous-recombination repair genes, PTEN and germline BRCA1/2 in cancers outside breast/ovarian indications. Clinical benefit included response or stable disease lasting at least 24 weeks.

## Fields

- Kind: Key paper
- Last checked: 2026-10-10
- Journal: npj Precision Oncology
- Year: 2024
- DOI: 10.1038/s41698-024-00634-6
- Authors: Piha-Paul SA, Tseng C, Leung CH, et al.
- Findings: Somatic BRCA1/2 cohort: four objective responses among 18 patients, ORR 22.2% (95% CI 6.4 to 47.6); six clinical-benefit events.; Posterior mean clinical-benefit rate 32.5% (90% credible interval 16.7 to 50.3) is a separate endpoint from objective response.; Breast examples included a somatic BRCA1 partial response and prolonged stable disease.
- What it means: Mixed, heavily pretreated cancers and no control arm; cannot compare its ORR directly with olaparib trials or establish postoperative benefit.
- Caveats: Mixed, heavily pretreated cancers and no control arm; cannot compare its ORR directly with olaparib trials or establish postoperative benefit.

## Sources

- Primary publication: https://doi.org/10.1038/s41698-024-00634-6
- PubMed record: https://pubmed.ncbi.nlm.nih.gov/39085400/

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Talazoparib](https://onco.cc/drugs/talazoparib/)
- trials: [Talazoparib molecular basket in advanced cancers](https://onco.cc/trials/nct02286687/)

---
JSON: https://onco.cc/api/v1/entities/paper-piha-paul-talazoparib-ddr-npj-2024.json